Citigroup’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$911K Buy
25,087
+8,750
+54% +$391K ﹤0.01% 3171
2025
Q4
$760K Sell
16,337
-4,459
-21% -$199K ﹤0.01% 3312
2025
Q3
$866K Sell
20,796
-35,983
-63% -$1.15M ﹤0.01% 3249
2025
Q2
$1.63M Sell
56,779
-93,271
-62% -$2.88M ﹤0.01% 2818
2025
Q1
$5.03M Buy
150,050
+29,291
+24% +$1.09M ﹤0.01% 1891
2024
Q4
$6.17M Buy
120,759
+55,934
+86% +$3.13M ﹤0.01% 1755
2024
Q3
$3.31M Buy
64,825
+33,755
+109% +$1.74M ﹤0.01% 2206
2024
Q2
$1.39M Sell
31,070
-216,980
-87% -$10M ﹤0.01% 2645
2024
Q1
$11.6M Buy
248,050
+145,739
+142% +$5.7M 0.01% 1165
2023
Q4
$3.64M Buy
102,311
+18,539
+22% +$569K ﹤0.01% 1805
2023
Q3
$2.49M Buy
83,772
+28,388
+51% +$585K ﹤0.01% 1845
2023
Q2
$998K Sell
55,384
-48,433
-47% -$966K ﹤0.01% 2843
2023
Q1
$1.67M Buy
103,817
+54,946
+112% +$1.02M ﹤0.01% 2144
2022
Q4
$894K Sell
48,871
-21,615
-31% -$381K ﹤0.01% 2704
2022
Q3
$1.38M Buy
70,486
+20,506
+41% +$418K ﹤0.01% 2455
2022
Q2
$932K Buy
49,980
+34,510
+223% +$689K ﹤0.01% 2720
2022
Q1
$340K Sell
15,470
-36,753
-70% -$744K ﹤0.01% 3759
2021
Q4
$1.48M Buy
52,223
+28,460
+120% +$702K ﹤0.01% 2874
2021
Q3
$500K Buy
23,763
+19,122
+412% +$400K ﹤0.01% 3611
2021
Q2
$87K Buy
4,641
+1,835
+65% +$32.2K ﹤0.01% 4568
2021
Q1
$43K Sell
2,806
-7,455
-73% -$116K ﹤0.01% 4778
2020
Q4
$145K Buy
10,261
+5,254
+105% +$73.2K ﹤0.01% 5237
2020
Q3
$78K Sell
5,007
-1,563
-24% -$23.9K ﹤0.01% 5284
2020
Q2
$115K Buy
6,570
+3,353
+104% +$57.2K ﹤0.01% 5462
2020
Q1
$47K Buy
3,217
+966
+43% +$19.8K ﹤0.01% 6016
2019
Q4
$56K Buy
2,251
+1,067
+90% +$20.3K ﹤0.01% 6212
2019
Q3
$18K Sell
1,184
-2,459
-67% -$47.8K ﹤0.01% 6792
2019
Q2
$92K Buy
3,643
+933
+34% +$23.1K ﹤0.01% 5949
2019
Q1
$61K Buy
2,710
+1,209
+81% +$29.7K ﹤0.01% 6169
2018
Q4
$45K Sell
1,501
-445
-23% -$12.5K ﹤0.01% 6314
2018
Q3
$56K Buy
+1,946
New +$57.8K ﹤0.01% 6424

Other funds holding CRNX